Compare CRVS & EVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRVS | EVAC |
|---|---|---|
| Founded | 2014 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.0M | 584.5M |
| IPO Year | 2016 | 2025 |
| Metric | CRVS | EVAC |
|---|---|---|
| Price | $7.69 | $10.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $13.75 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 42.2K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $9.90 |
| 52 Week High | $9.60 | $10.17 |
| Indicator | CRVS | EVAC |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | N/A |
| Support Level | $7.28 | N/A |
| Resistance Level | $7.86 | N/A |
| Average True Range (ATR) | 0.42 | 0.00 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 29.01 | 0.00 |
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
EQV Ventures Acquisition Corp II is a blank check company.